Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CELU vs LVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LVTX Captures Overall Composite Edge (67.0 BUY vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars

LVTX Overall Winner 6-Pillar Tally: CELU 3 – 2 LVTX (1 Tie) Matrix Metrics: CELU 1 – 7 LVTX

As of Nov 20, 2026, LAVA Therapeutics N.V. (LVTX) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (67.0/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 7–1 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus LVTX at $1.74 (N/M Forward P/E, -431.9% operating margin).

  • Growth vs. Quality Trade-Off: LVTX earns the overall head-to-head edge with a stronger Unified Composite Score (67.0/100 BUY vs. CELU 42.9/100 HOLD) and -0.02β · 49% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELU vs LVTX
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08
LVTX NASDAQ Head-to-Head Winner
LAVA Therapeutics N.V. Ordinary Shares
Pharmaceutical Preparations
$1.74
-3.87% 1D
Market Cap $45.8M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol -0.02β · 49% Vol
Unified Composite Score
67.0 / 100 BUY
Tech 75.0 Fund 63.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $1.65 · SMA50: $1.59

6-Pillar Scorecard Institutional Category Breakdown (CELU 3 – 2 LVTX)

Columns: Metric · CELU · LVTX
1. Valuation Multiples CELU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.7x 9.2x
2. Growth & Scale LVTX
Revenue Growth (YoY) -5.3% +1313.6%
Earnings Growth (YoY) -61.3% +0.0%
TTM Revenue (USD) $19M $5.0M
Market Cap $15.2M $45.8M
3. Profitability & Quality LVTX
Gross Margin 19.2% 100.0%
Operating Margin -254.0% -431.9%
Net Profit Margin -245.7% 0.0%
Return on Equity (ROE) -6367.2% -101.5%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$8.9M -$21M EBITDA
Cash Flow Margin -47.8% N/A
Net Cash / Leverage $35M Net Debt $0.48 Book/Sh · -101.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CELU
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 116.6% (50th %ile) N/A (N/A)
Put/Call OI Skew 3.60x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELU (1) vs LVTX (7)
Institutional Metric CELU LVTX Criterion Row Edge
Market Capitalization
Scale
$15.2M $45.8M Larger Scale LVTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-5.3% +1313.6% Higher Growth LVTX
Operating Margin (TTM)
Profitability
-254.0% -431.9% Higher Margin CELU
Net Profit Margin
Profitability
-245.7% 0.0% Higher Margin LVTX
Return on Equity (ROE)
Capital Efficiency
-6367.2% -101.5% Higher ROE LVTX
52-Week Range Position
Momentum
2% ($0–$3) 77% ($1–$2) Stronger Trend LVTX
Beta / 30D Volatility
Risk Regime
2.01β · 135% Vol -0.02β · 49% Vol Lower Realized Risk LVTX
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 67.0 / 100 (BUY) Higher Composite LVTX
Trailing 12M Revenue (USD)
Operating Scale
$19M $5.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.2% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.7x EV/Rev N/M PEG · 9.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.9M ($35M Net Debt) -$21M EBITDA ($0.48 Book/Sh · -101.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELU +5.05 pp
CELU: +1.18% · LVTX: -3.87%
3M Horizon CELU +5.05 pp
CELU: +1.18% · LVTX: -3.87%
6M Horizon CELU +5.05 pp
CELU: +1.18% · LVTX: -3.87%
1Y Horizon CELU +5.05 pp
CELU: +1.18% · LVTX: -3.87%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELU vs LVTX. Trailing 12-month operating profitability (CELU -254.0% vs LVTX -431.9%) and valuation multiples (CELU N/M vs LVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CELU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin19.2%
Op. Margin-254.0%
ROE / Fwd P/E-6367.2% · N/M
LVTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-431.9%
ROE / Fwd P/E-101.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LVTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LVTX Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $45.8M market capitalization and -431.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELU vs LVTX Key Questions & Quantitative Answers

As of Nov 20, 2026, LAVA Therapeutics N.V. (LVTX) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (67.0/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 7–1 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus LVTX at $1.74 (N/M Forward P/E, -431.9% operating margin). Growth vs. Quality Trade-Off: LVTX earns the overall head-to-head edge with a stronger Unified Composite Score (67.0/100 BUY vs. CELU 42.9/100 HOLD) and -0.02β · 49% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile LVTX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LVTX leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with LVTX at +1313.6% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -431.9% operating margin). On trailing 12-month operating scale, CELU generates $19M in USD-normalized revenue versus $5.0M for LVTX. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LVTX.

CELU screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas LVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus LVTX (-101.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, LVTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.